June 15, 2026 · Gynecologic oncology · DOI: 10.1016/j.ygyno.2026.06.006

Could chemotherapy response score act as a surrogate marker of response to PARP inhibitor maintenance treatment in patients with advanced ovarian cancer?

Listen to this summary

The authors aimed to determine if the Chemotherapy Response Score (CRS) could serve as a surrogate marker for predicting the benefit of PARP inhibitor maintenance treatment in patients with advanced ovarian cancer. Their findings indicate that patients with a higher CRS (2-3) experienced improved progression-free survival (PFS) with PARP inhibitor maintenance, while those with a lower CRS (1) did not show any survival benefit. This suggests that CRS may be a useful tool for guiding treatment decisions, especially in cases where genetic testing is not readily available.

Anne-Marie Bergeron, Marta Kisiel, Melissa Lavecchia, Sarah Mah, Vanessa Carlson, Julie My Van Nguyen, Clare J Reade, Lua R Eiriksson, Waldo G Jimenez, Alice Lytwyn, Andra Nica

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play